VIDEO: SUNLIGHT data ‘paves the road forward’ for refractory colorectal cancer treatment
Click Here to Manage Email Alerts
In this video interview, Cecilia Monge, MD, MPH, FACP, from the NCI Center for Cancer Research at NIH, discussed the SUNLIGHT trial data presented at ASCO Gastrointestinal Cancers Symposium.
The data showed that adding bevacizumab(Avastin, Genentech) to trifluridine/tipiracil (Lonsurf; Taiho Oncology, Servier) improved OS vs. trifluridine/tipiracil alone among adults with refractory metastatic colorectal cancer.
“There were very limited options in this space,” Monge said. “This is also a space where we’re in dire need of moving the needle forward and of new research. It has been many years since we had a new option in ... metastatic colorectal cancer in the third-line systemic setting.”
She added that seeing a median OS of 10.8 months in this group of patients “is really exciting and paves the road forward.”
Reference:
- Tabernero J, et al. Abstract 4. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 19-21, 2023; San Francisco.
Collapse
Healio Interview
Click Here to Manage Email Alerts